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Background: In the investigation of lung cancer, current practice in many healthcare systems 
would support bronchoscopy regardless of CT findings i  patients with hemoptysis. We 
sought to identify the cause, the diagnostic yield of CT and bronchoscopy and the 
requirement for bronchoscopy in at risk patients with hemoptysis with a normal CT scan 
through our rapid access lung cancer clinic (RALC). 
 Methods: Initially, a chart review was performed on all patients with hemoptysis (2011-
2012) and thereafter a prospective analysis was performed (2013-2016). 
Results: Our analysis represents the largest study to date in outpatients with hemoptysis. In 
our retrospective study, 155 patients reported hemoptysis. Causes were lower respiratory tract 
infections (RTIs) (47%) and lung cancer (16%). Our prospective study included 182 patients. 
The causes of hemoptysis were RTIs (50%) and lung ca cer (18%).  There were no false 
negative CT-scans for lung cancer. 47/57 present with lung cancer underwent bronchoscopy 
and 43/47 were positive for lung cancer (92%). Patients with hemoptysis and lung cancer 
have a higher stage of malignancy with a predominance of squamous cell lung carcinoma. 
Smoking status, the duration of hemoptysis or description of hemoptysis were not predictive 
of lung cancer however lung cancer was not identified in patients age <50. 
Conclusions: One sixth of patients presenting with hemoptysis to our lung cancer clinic had 
lung cancer. No patient identified with cancer relat d haemoptysis had a CT negative for lung 
cancer and a combination of bronchoscopy plus endobronchial ultrasound trans- bronchial 
needle aspiration (EBUS-TBNA) in those patients with a CT suspicious of lung cancer is 
























CT:   Computerized Tomography 
RALC:  Rapid Access Lung Cancer 
EBUS-TBNA:  Endobronchial Ultrasound guided Trans -bronchial Needle Aspiration 























Hemoptysis is defined as the expectoration of blood that originates from the pulmonary 
parenchyma or airways. Most cases are benign, self-limiting events but in less than 5% cases 
it may be life threatening which warrants urgent investigation and treatment [1]. Common 
causes of hemoptysis include chronic bronchitis, bronchiectasis, pneumonia, fungal 
infections, tuberculosis, and malignancy. Many patients however present with pseudo-
hemoptysis, that is blood originating from nasopharynx or gastrointestinal tract and it is 
important to rule out bleeding from these alternative sites. Guidelines regarding the referral 
and investigation of hemoptysis in patients at riskfor lung cancer are available and in general 
consistent [2, 3]. The recommendations include a chest x-ray in all and progression to a 
computerized tomography (CT) scan and referral to a specialist in patients with an abnormal 
chest x-ray or normal chest x-ray who are older, or smokers or who have persistent 
hemoptysis. The previous UK NICE guidelines (which will be updated in 2018) 
recommended bronchoscopy in all patients who are und rgoing CT imaging [2].  However, 
the recently published “National Optimal Clinical Pathway for suspected and confirmed lung 
cancer: Referral to treatment” report by a UK Independent Cancer Taskforce has suggested a 
change in strategy and includes patient pathway flow diagrams. It recommends triaging 
patients who have symptoms suggestive of lung cancer or a suspicious chest x-ray to CT 
scan. If the CT scan is negative for cancer and sympto s are self-limited, the patient does not 
require a bronchoscopy to rule out lung cancer. If the patient has persistent hemoptysis but a 
CT negative for cancer, the patient may be triaged to a non-cancer clinic with or without 
bronchoscopy (4). However, there is a paucity of guidance regarding the investigation of 














In Ireland in 2010, the referral pathway for patients with symptoms suspicious of lung cancer 
being referred to our designated cancer centers in our ational health system was streamlined. 
Patients presenting with hemoptysis to primary care are now referred to dedicated Rapid 
Access Lung Cancer (RALC) clinics for review and diagnostic testing. In parallel to UK 
NICE guidelines, it is our current practice to proceed with CT scan and bronchoscopy on all 
patients who have hemoptysis referred to RALC clini excluding patients with pseudo-
hemoptysis, who have poor performance status or do not consent, or where clinic radiological 
work-up suggests another cause of hemoptysis not requiring bronchoscopy (e.g. pulmonary 
embolus). It is important to state that this referral pathway accounts for approximately 50% 
of all patients diagnosed with lung cancer at our institution (approximately 200/year) and 
does not include symptomatic patients presenting to the emergency department with lung 
cancer. The role of bronchoscopy in the evaluation of sub massive hemoptysis with CT 
imaging suggesting a central airway lesion is undisputed. However, the role of bronchoscopy 
is controversial in patients reporting hemoptysis with normal CT. We sought to identify the 
cause, the diagnostic yield of CT scan and bronchoscopy and the requirement for 
bronchoscopy in at risk of patients with hemoptysis with a normal CT scan through our rapid 




















METHODS: We present data from both an initial retrospective followed by a subsequent 
prospective study. After local ethical approval from the UCC-CUH Cork research ethics 
board, a chart review was performed on all patients pre enting with hemoptysis to the RALC 
at Cork University Hospital in 2011-2012 (ECM 4(d) 05/02/2013). The gold standard 
diagnosis for the cause of hemoptysis was a composite f confirmatory pathological or 
microbiological diagnosis with at least 6 months’ clini  radiological follow-up. The cause of 
hemoptysis was broken down to the number of groups including cancer, infection, 
bronchiectasis, pulmonary embolus and idiopathic. A negative bronchoscopy meant the 
bronchoscopy did not identify the cause of hemoptysis not that there was no bleeding from 
the airway. If, with completion of above follow up, no cause for hemoptysis was identified, it 
was labeled idiopathic. However, if inadequate follow up was performed, hemoptysis was 
labeled “no-gold standard diagnosis”. Simple statistics were used to compare groups. Based 
on our retrospective analysis, after ethical approval with waiver of requirement of patient 
consent, a prospective study was performed on all patients presenting to our Rapid Access 
Lung Cancer (RALC) clinic between 2013 and January 2016 (ECN 3(nn) 06/08/2013). Data 
was collected on a proforma at the time of presentatio  to RALC and thus more compete than 
our retrospective study. In both studies, we acquired data on the following variables: age, 
gender, smoking status, duration of hemoptysis, current medications, commencement and 
response of antibiotics, results of CT scan and bronch scopy. In our Centre, since 2012 the 
majority of CT studies were done on a scanner which was at least 64-slice VCT capable. 
Prior to 2012 some scans were done on a 4-slice scanner but still with multi-slice CT-
technology. CT images typically include all of both lung fields with upper abdominal slices. 
Bronchoscopy is performed under conscious sedation w th flexible bronchoscopes with 
complete evaluation of airway anatomy. Where appropriate, endobronchial ultrasound guided 














probe ultrasound is also utilized. Our radiology, microbiology and pathology departments 
were not aware of our protocol and thus reporting of CT images and tissue samples were not 
biased by our study protocol.  
Descriptive statistics were used for demographics, Categorical variables were compared 



























RESULTS: In total 337 patients referred to RALC with hemoptysis were included, 155 cases 
in the retrospective study and 182 cases in the prospective study (Figure 1). Patient 
demographics and etiology of hemoptysis are presentd i  Table 1.  
 
Duration and Type of hemoptysis: 
Hemoptysis was classified as single if there is one episode, persistent if bleeding continues 
for longer than 2 weeks and on-persistent if it lasts less than 2 weeks. In our retrospective 
review the duration of haemoptysis was single episode n=31 (20% of patients), n=77 (50%) 
non-persistent (<2 weeks) and persistent (>2 weeks) n=46 (30%). Persistent haemoptysis was 
significantly more frequent in patients diagnosed with lung cancer (16/24 (66%) p=.0001). 
Similarly, in our prospective study, 41.8(23.5%) patients presented with a single episode of 
hemoptysis, 41.8% (N=76) with non-persistent (<2 weeks) hemoptysis and 35.9% (N=65) 
with persistent hemoptysis (> 2 weeks). Lung cancer patient were more likely to have 
persistent hemoptysis (23/33 (70%) s (p=0.0034)). However, it is important to note that of the 
46 retrospective patients presenting with persistent h moptysis, only 16 had cancer (35%) 
and of the 65 prospective patients with persistent h moptysis, only 23 had cancer (35%).  
We also analyzed the association between hemoptysis type and lung cancer in our 
prospective study. However, there was no association between frank blood (3/33 vs 30/149) 
or blood mixed with sputum and lung cancer (p=0.712). Lung cancer was also not more 

















Smoking Status:  
The majority of patients presenting to our RALC clinic with lung cancer were current or ex-
smokers 291/337. (52/291(18%)) of smokers had hemoptysis and lung cancer. However, 5/57 
patients with hemoptysis and lung cancer were never smokers (8.7%). In never-smokers 
presenting with hemoptysis (46), 5 had lung cancer (10.86%) which was similar to our total 
group of patients (57 cancers /337 hemoptysis (17%). Hence, there was no difference in the 
incidence of lung cancer between smokers with hemoptysis (current or ex) and never smokers 
with hemoptysis (p=0.294). 
 
CT scan in investigation of hemoptysis: (Table 2) 
In both studies, all patients had chest CT performed as a part of their investigation. In our 
retrospective analysis 24 (16%) had lung cancer and all CTs were positive for lung cancer. 
Similarly, in our prospective study, 33 (18%) had lung cancer and all had chest CT positive 
for lung cancer. In combination, the specificity of CT imaging in patients with lung cancer 
for hemoptysis was 100%. Of the 57 patients with a CT scan suggestive of lung cancer, 42 
had a mass or lung nodule (78%), 8 (14%) had an area of parenchymal opacity or 
consolidation and 7 (12%) had an endobronchial lesion. 
 
Bronchoscopy in Investigation of hemoptysis: (Table 3 and 4) 
In our retrospective study, 19/24 (79%) lung cancer patients underwent bronchoscopy for the 
investigation of hemoptysis. 18/19 (95%) bronchoscopies were diagnostic for lung cancer. 














TBNA to evaluate hemoptysis. Similarly, our prospective study showed 28/33 (85%) had 
bronchoscopy to investigate the cause of hemoptysis. 25/28 (89.2%) had bronchoscopy 
diagnostic for lung cancer. 21/28 (75%) had both bronchoscopies with EBUS-TBNA. In 
retrospective study 102/155 (66%) patients with hemoptysis underwent bronchoscopy 
.71/102(70%) bronchoscopy showed no etiology of hemoptysis. In prospective study 142/182 
(78%) patients had bronchoscopy to investigate the cause of hemoptysis. In 99/142(70%) 
bronchoscopy did not identify any cause of hemoptysis. In our study most non-malignant 
etiologies of hemoptysis on bronchoscopy were lower respiratory tract infections (pneumonia 
and bronchitis).In total 57/336 (17%) had hemoptysis secondary to lung cancer and 47/57 
underwent bronchoscopy and 43/47 were positive for lung cancer (92%).  
 
Hemoptysis and Lung cancer stages: (Table 5) 
40/57 (70%) of lung cancer patients presenting to RALC had stage 3-4 lung cancer which is 
significantly higher than we previously reported for all patients presenting with lung cancer 
to our RALC (49%) (p=.0067) [4]. 
 
Histological subtypes of lung cancer: 
In a similar fashion to our overall lung cancer cohort presenting to RALC, most tumors were 
non-small cell lung cancer (NSCLC) (46/57 (80.7%).  However, more lung cancer patients 
with hemoptysis had squamous cell cancer NSCLC (27/46 (59%)) than non-squamous 















DISCUSSION: Our study of 337 patients which includes a large modern prospective cohort 
presenting to a lung cancer clinic with hemoptysis ha allowed us to analyze in detail the 
utility of investigations performed for lung cancer and investigate patient symptom and tumor 
types related to lung cancer in patients with hemoptysis. 
Given the fact that chest x-rays miss many patients with lung cancer and hemoptysis [6, 7], it 
is routine practice that all patients undergo CT imaging. Chest CT has the ability to identify 
abnormalities in patients with hemoptysis secondary to lung cancer and also provide accurate 
staging compared to chest x-rays and standard bronchoscopy [1, 8]. It has the ability of 
visualizing distal airways beyond the level of bronchoscope and found to be more sensitive 
than bronchoscopy in evaluating endobronchial lesions [9 -12]. Guidelines and studies have 
also suggested that in all patients with suspected lung cancer presenting with hemoptysis 
(excluding massive hemoptysis or an unstable patient), CT should be carried out before 
bronchoscopy [2, 3, 8, 13]. In those patients who have a CT negative for lung cancer, the 
recent UK National Optimal Pathway publication suggested that further testing including 
bronchoscopy is not required to rule out cancer and bronchoscopy may be performed at the 
discretion of the physician triaging the patient where hemoptysis is not self-limited [4]. Chest 
CT is more efficient and superior, noninvasive and highly useful in the clinical context of 
underlying causes of hemoptysis [8 ,10,14]. It was also found that CT scan localize bleeding 
site in 63% to 100% patients with hemoptysis [10,15]. In a study by Revel et al [16], CT and 
bronchoscopy findings of 80 patients were reviewed ith haemoptysis. CT was more 
efficient than bronchoscopy for the etiological investigation of the bleeding (77% vs 8%, 
respectively). 
McGuinness [8], found the diagnostic yield of CT and bronchoscopy to be 61% and 43% 
respectively, and that CT was positive in 50% of cases with a negative bronchoscopy. 














findings have positive CT. In a study by Hirshberg t al [11], 208 patients with hemoptysis 
were reviewed, 70 (34%) patients had CT chest and 47/70(67%) had positive findings on CT 
scans .137(66%) out of 208 had bronchoscopy performed and 57(42%) of them had positive 
bronchoscopy. CT scan missed three lung cancer cases in patients with hemoptysis. This 
study concluded that the combined use of CT chest and bronchoscopy gave the best 
diagnostic yield for lung cancer. A recent Danish study [18] concluded that 16 of 269 patients 
with hemoptysis had lung cancer; all 16 patients had positive CT scan. No patients with 
normal CT scan had a positive bronchoscopy for malign ncy. s. Similarly, in our 337 patients 
we identified no patient with lung cancer who had a false negative chest CT scan. In our 
Centre, a combination of bronchoscopy plus EBUS-TBNA is 92% sensitive for lung cancer 
in patients presenting to a rapid access lung cancer clinic with hemoptysis.   
In Table 6, we have listed all publications [8, 11, 14 ,16,18-22] that we could identify 
reporting on CT imaging in patients with hemoptysis. Combined with our study this table 
includes a total of 2053 patients presenting with hemoptysis, of whom 262 (13%) had lung 
cancer and CT missed six cases of lung cancer (98% sensitivity). Three of these cases were 
from the 1980s with poor quality CT imaging [11]. Therefore, in patients with hemoptysis, 
the occurrence of CT occult neoplasm using modern day CT imaging is extremely rare. Of 
note in high risk asymptomatic smokers undergoing screening for lung cancer, a recent large 
publication suggested the addition of Auto Fluorescence Bronchoscopy to low-dose CT was 
futile in the detection of lung cancer. We are not sta ing that despite the quality of current CT 
imaging, CT occult neoplasms including carcinoma do not occur [23]. However, we postulate 
that these neoplasms are too small to cause hemoptysis or other symptoms and thus maybe 















Regarding younger patients with hemoptysis, in our st dy patients diagnosed with lung 
cancer were older with mean age of 61 and youngest patient with hemoptysis and lung cancer 
was 52 years old. In actual fact in all of these studies of 2053 patients with hemoptysis, no 
lung cancer was diagnosed in patients less than 50 years old. We therefore question the utility 
of investigations for lung cancer in younger patients with hemoptysis in future guidelines, 
however in this population CT imaging identifies other causes such as infection and 
bronchiectasis.  
Similarly, to previous studies, we identified nonsmokers with hemoptysis and lung cancer. In 
the cohort of Hirshberg et al [11], 3 (14.2%) lung cancer patients were non-smokers. In our 
study 5 out 57 cases of lung cancers were non-smokers and there was no difference in the 
incidence of lung cancer between smokers and non-smokers (p=0.294). Thus, in our opinion 
smoking status should not influence investigations f r lung cancer in patients with 
hemoptysis. 
In our study, patients with lung cancers had hemoptysis of long duration. McGuinness et al 
[8] found persistent hemoptysis in 5 out of 7 lung cancer cases, similarly Jackson et al [24] 
and Jacob et al [25] also demonstrated that persistnt hemoptysis was significantly more 
frequent in patients who had lung cancer. We found that two thirds of the patients with lung 
cancer had persistent hemoptysis. However, given th fact that many patients without cancer 
presented with persistent hemoptysis and 4 patients with cancer presented with single episode 
hemoptysis, in our opinion the duration of hemoptysis should not influence investigations. 
Similarly, we did not find that patient reporting on quantity or type of hemoptysis (frank vs 
blood mixed with sputum) useful. 
We identified differences in the histological subtype of type of lung cancer associated with 
hemoptysis between our study and prior studies. Small cell carcinoma found to be most 














al [22] noted 76% non- small cell lung cancer (NSCLC) and 7.7% small cell lung cancer. 
However, in our study more patients presented with hemoptysis secondary to NSCLC 
(80.7%) and 59% of NSCLC were squamous cell which was statistically a higher incidence 
of squamous cell cancer than we have previously published (26%) [5]. Regarding the stage of 
presentation, 40/57(70%) of lung cancer patients pre enting to RALC had stage 3-4 lung 
cancer which is significantly higher than we previously reported for all patients presenting 
with lung cancer to our RALC (p=.0067) [5].  
 
CONCLUSIONS:  
In conclusion, in patients with hemoptysis being investigated for lung cancer, a negative CT 
scan for malignancy rules out lung cancer as the cause of hemoptysis with 98% sensitivity 
regardless of patients age, smoking status or duration of bronchoscopy. A decision to proceed 
to bronchoscopy may be made at the discretion of the triaging physician in hemoptysis that is 
not self-limited as it may help to identify other causes of hemoptysis. In patients with 
hemoptysis caused by lung cancer, bronchoscopy with EBUS-TBNA is accurate in 
diagnosing malignancy. Patients with hemoptysis and lu g cancer tend to have a higher stage 
of malignancy with a predominance of squamous cell carcinoma. Smoking status, the 
duration of hemoptysis or description of hemoptysis should not influence the investigation of 
hemoptysis in patients referred for investigation of lung cancer. 
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Bronchoscopy findings in 337 Patients with Hemoptysis. 
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*40/57(70%) of lung cancer patients presenting to RALC had stage 3-4 lung cancer which is 
significantly higher than we previously reported for all patients presenting with lung cancer 





































Table 6: Sensitivity of CT Thorax for Lung Cancer in Patien s with Hemoptysis: Comparison 
with other studies. 
Journal 
published 

























269 16 (6%) 0 
Clinical 
Respiratory J 
Uzun  et al Prospective 2005-
2009 
178 51(28.6%) 0 
Respir Med Lee et al Retrospective 2003-
2009 
228 1(0.43%) 1 
Portuguese J 
Pulmonology 
Pires et al Retrospective 2004-
2008 












184 24(13%) 0 
Am J 
Roentgen 
Revel et al Retrospective 1995-
1999 
80 9(11%) 0 









57 7(12%) 0 
*Total    2053 262(13%) 6(98%)* 
*In 2053 patients presenting with hemoptysis, sensitivity of CT scans for lung cancer 
256/262=98% 
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*40/57(70%) of lung cancer patients presenting to RALC had stage 3-4 lung cancer which is 
significantly higher than we previously reported for all patients presenting with lung cancer 
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57 7(12%) 0 
*Total    2053 262(13%) 6(98%)* 
*In 2053 patients presenting with hemoptysis, sensitivity of CT scans for lung cancer 
256/262=98% 




























CT scan positive for lung cancer 
24 (100%)
131 (84%) negative for Lung 
cancer
Subsequent cancer diagnosis 






CT scan positive for lung cancer 
33 (100%)
149 (82%) Negative for Lung 
Cancer
Subsequent cancer diagnosis 















• In patients with hemoptysis being investigated for lung cancer, a negative CT 
scan for malignancy rules out lung cancer as the cause of hemoptysis with 
98% sensitivity regardless of patients age, smoking status or duration of 
bronchoscopy. 
• In patients with hemoptysis caused by lung cancer, bronchoscopy with EBUS-
TBNA is accurate in diagnosing malignancy. 
• Patients with hemoptysis and lung cancer tend to have a higher stage of 
malignancy with a predominance of squamous cell carcinoma. 
• Smoking status, the duration of hemoptysis or description of hemoptysis 
should not influence the investigation of hemoptysis in patients referred for 
investigation of lung cancer. 
• Recently published UK Optimal Pathways for Lung Cancer suggests a 
significant change in management of patients with suspected lung cancer and 
similar to our findings, it suggests that in patients with symptoms suggestive 
of lung cancer but a negative CT for lung cancer, bronchoscopy is not required 
to rule out lung cancer 
(http://content.smallerearthtech.co.uk/system/file_uploads/16086/original/Nati
onal_Optimal_LUNG_Pathway_Aug_2017.pdf) 
